Mesalazine, also known as mesalamine, is used in the supportive management of conditions characterized by periods of heightened symptoms affecting the digestive tract, primarily Inflammatory Bowel Disease (IBD). Its main therapeutic uses are the treatment of key IBD manifestations, including ulcerative colitis and Crohn's disease.

The medication is applied in addressing a key challenge in these conditions: symptoms related to inflammatory or irritative states. It is considered relevant for easing these symptoms by helping to reduce swelling (inflammation). This targeted therapeutic action is used both in clinical settings that involve acute or disruptive episodes (flare-ups) and may be part of symptomatic management to help reduce the recurrence of periods involving heightened symptoms.

By easing this inflammation, mesalazine provides support that helps ease the overall symptom burden and contributes to improved comfort for patients experiencing symptoms related to physical discomfort and systemic imbalance. It is generally used to help with the management of symptomatic phases and to assist with maintaining functional stability.

Quick Fact: Relief for Symptoms related to inflammatory or irritative states

Who Can and Cannot Use Mesalazine? — Official Regulatory Information

The eligibility profile for Mesalazine (5-ASA) is determined strictly by regulatory guidelines, classifying populations into allowed, restricted, and contraindicated groups.

Eligibility Scope

Classification	Eligible Population	Restriction/Exclusion Condition
Allowed Use	Adults (18+) and Pediatric patients (typically 5 or 6 years and older) for specific formulations.	Must not have absolute contraindications.
Contraindicated	None.	Hypersensitivity to salicylates, aminosalicylates, or product ingredients; Severe hepatic impairment; Severe renal impairment.
Conditional Use	Patients with mild to moderate renal or hepatic impairment.	Use requires caution and monitoring of organ function.

Age- and Condition-Specific Rules

Age-Related Eligibility: Use is established for adults. For children, eligibility is product-specific, with safety not established below a minimum age (often 5 or 6 years). Older adults require caution due to the higher potential for reduced organ function.

Pregnancy and Lactation: Use during pregnancy is often continued to maintain disease control but is typically recommended only if clearly needed. During lactation, use is generally acceptable, but the breastfed infant must be monitored for diarrhea or other signs of hypersensitivity.

Organ Impairment: Mesalazine is contraindicated in severe hepatic or renal impairment and requires caution in mild-to-moderate cases.

Interactions with other medicines and products

Regulatory authorities document specific interaction patterns for mesalazine (5-Aminosalicylic Acid) that primarily concern additive toxicity risks and the modification of co-administered drug exposure.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance Class	Officially Documented Interaction Outcome
Thiopurines (e.g., Azathioprine, Mercaptopurine, Thioguanine)	Co-administration leads to an increased risk of blood dyscrasias due to elevated systemic exposure of the thiopurines' active metabolites. Regulatory labels require monitoring of blood cell counts during concurrent use.
Nephrotoxic Agents (e.g., Non-Steroidal Anti-Inflammatory Drugs, NSAIDs)	Concurrent use may increase the risk of renal adverse reactions (nephrotoxicity). The risk is considered clinically significant, particularly for patients with known renal impairment, where monitoring of renal function is advised.
Coumarin Derivatives (e.g., Warfarin)	Mesalazine may potentiate or diminish the anticoagulant effect of the coumarin derivative.

Other Documented Interactions

Formal regulatory documents also note that mesalazine may cause spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection. Additionally, urine containing mesalazine or its metabolite may exhibit a red-brown discoloration upon contact with sodium hypochlorite bleach (a chemical reaction, not a systemic effect).

There are no formal drug-to-drug contraindicated combinations explicitly listed in regulatory interaction sections, and no mandatory timing separation rules are documented for co-administration.

Mesalazine's mechanism of action is distinctly topical and poly-pharmacological, relying on multiple complementary actions concentrated directly within the inflamed lining of the intestine. The drug’s core physiological action is the localized modulation of inflammatory signaling.

Blocking the Genetic Switch for Inflammation

Mesalazine, or 5-ASA, primarily acts by inhibiting the key inflammatory transcription factor, NF-kappaB, within mucosal immune cells. This molecular action prevents the cell from activating the genes that instruct it to produce and release inflammatory messengers, known as cytokines (e.g., TNF-alpha and interleukins). This interference at the gene transcription level results in the down-regulation of the localized inflammatory program.

Interference with Pro-Inflammatory Chemical Production

A parallel mechanistic domain involves the inhibition of enzymes in the Arachidonic Acid Cascade, specifically Cyclooxygenase (COX) and Lipoxygenase (LOX). By blocking these pathways, the drug dramatically reduces the local synthesis of pro-inflammatory prostaglandins and leukotrienes that are potent mediators of inflammation. This action contributes to reducing the synthesis of mediators associated with increased vascular permeability.

Dual Protective and Regulatory Mechanisms

Mesalazine also exerts a protective effect by acting as an antioxidant, directly neutralizing harmful Reactive Oxygen Species (ROS) or free radicals that cause cell damage in inflamed tissue. Furthermore, it supports cellular regulation by activating the nuclear receptor PPAR-gamma. Together, these actions support the preservation of cellular integrity and contribute to a lowered state of oxidative stress in the mucosa.

Mesalazine administration is strictly governed by the need to deliver the active ingredient directly to the inflamed lining of the intestine. The medicine is officially administered via two routes: oral forms (delayed-release tablets, capsules, and granules) and rectal forms (enemas, suppositories, and rectal suspensions). The choice of administration route is typically determined by the location of the disease in the bowel.

---

Dosing and Frequency Patterns

Dosing is structured around the phase of treatment. For the induction of remission during acute episodes, oral doses typically range from 2.4 g to 4.8 g per day. For the maintenance of remission in a long-term plan, the daily dose is generally lower, ranging from 1.2 g to 2.4 g. These daily totals may be administered either once daily or in divided doses throughout the day, depending on the specific formulation.

---

Administration Requirements

Oral delayed-release tablets and capsules must be swallowed whole and not crushed, broken, or chewed; this is a mandatory procedural instruction to preserve the specialized coating necessary for targeted delivery to the colon. Instructions regarding the timing of administration vary: some oral preparations are taken with food, while others require administration on an empty stomach. Rectal products are often used for a short, defined course of therapy, whereas oral administration is typically a continuous, long-term plan for maintaining stability. Adequate hydration is also instructed during the period of use.

Mesalazine: Recent Clinical Evidence

Research evaluating mesalazine (also known as 5-aminosalicylic acid or 5-ASA) has been conducted in multiple settings to understand its potential role in the management of inflammatory bowel diseases (IBD), specifically ulcerative colitis (UC) and Crohn's disease (CD).

Studies describe mesalazine as an agent that is thought to act locally on the lining of the bowel to influence inflammatory processes. Research has primarily focused on whether its use is associated with maintaining remission and reducing symptom activity in UC.

---

Key Findings from Clinical Evaluations

In numerous trials, mesalazine was evaluated for its potential to affect patient outcomes, with findings focusing on changes in disease activity and symptom severity over specified periods. The evidence base for UC management is more extensive than that for CD.

• Ulcerative Colitis (UC): Studies investigated whether the use of mesalazine was associated with the induction and maintenance of remission. Findings generally report a difference in remission rates when compared to placebo in patients with mild-to-moderate UC.
• Crohn's Disease (CD): Research examining mesalazine in the management of CD has been conducted, but the results were mixed, and it is not yet clear whether its use offers a significant clinical benefit in this population.

Safety and Tolerability Profile

Research into mesalazine included both short-term and long-term use. Data related to the tolerability of different delivery formulations (e.g., oral, topical) were reported in the research findings.

• Commonly reported side effects in the trials included minor gastrointestinal discomfort, headache, and skin reactions. Rare, but serious, reports regarding kidney and heart conditions were reported in the research findings, which must be considered during clinical assessment.

Key Studies & References

1. Mesalazine: Drug Information
2. Mesalazine (5-Aminosalicylic Acid) and Inflammatory Bowel Disease: A Review of Clinical Evidence and Mechanisms of Action

Common questions about Mesalazine (FAQ)

Q: What is Mesalazine used for?

A: Mesalazine is authorized for the treatment and management of mild to moderate ulcerative colitis (UC). It may also be used to help maintain remission after symptoms have improved.

---

Q: How does Mesalazine work?

A: Research suggests Mesalazine is an anti-inflammatory medication that acts locally within the gut (intestines). It is thought to work by inhibiting certain inflammatory processes that contribute to the symptoms of UC.

---

Q: What are the common side effects of Mesalazine?

A: The most frequently reported adverse effects in clinical trials tend to be mild and may include headache, nausea, abdominal discomfort, and flatulence. These reports typically resolve with continued treatment or dose adjustment.

---

Q: Can Mesalazine be taken during pregnancy?

A: Decisions regarding the use of Mesalazine during pregnancy should be made in consultation with a healthcare provider. Observational studies have generally not shown an increased risk of birth defects; however, caution is typically advised, and a risk-benefit assessment is necessary.

Official Storage Requirements

Mesalazine must be stored at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from moisture and to keep the medication in its original, tightly closed container.

Handling and Safety

The product must not be frozen. To ensure child safety, mesalazine must be kept out of the reach and sight of children. Certain formulations, such as suppositories and enemas, also require protection from light.

Disposal Instructions

Disposal of any unused or expired mesalazine must be conducted according to local requirements. The medicine is officially restricted from being disposed of via common household waste or wastewater to prevent environmental contamination.